FLT3 and acute myeloid leukemia: Better CR was accomplished by FLT3i in untreated AML (RR 0.88, <i>p</i> = 0.04) and refractory and relapsed <i>FLT3</i>(+) AML (rrAML) (RR 0.61, <i>p</i> < 0.01) compared to non-FLT3i arm, followed by improved survival (untreated AML: OS, HR 0.76; EFS, HR 0.67; RFS, HR 0.72; all <i>p</i> < 0.01; <i>FLT3</i>(+) rrAML: OS, HR 0.60, <i>p</i> < 0.01; RFS, HR 0.40, <i>p</i> = 0.01).